Lang Stefan J, Böhringer Daniel, Reinhard Thomas
Klinik für Augenheilkunde, Universitätsklinikum Freiburg, Medizinische Fakultät, Albert-Ludwigs-Universität Freiburg.
Klin Monbl Augenheilkd. 2019 Feb;236(2):169-172. doi: 10.1055/s-0043-109692. Epub 2017 Jul 6.
Gelatinous corneal dystrophy is a very rare disease in Europe and North America. Patients suffer from pain, photophobia and loss of vision, usually before the age of 20. Transplantation of limbal stem cells was proposed due to the high rate of recurrence after conventional penetrating keratoplasty. We present the results of penetrating limbokeratoplasty, a combined transplantation of cornea and limbal stem cells, in patients with gelatinous corneal dystrophy.
We present a series of 7 consecutive eyes with gelatinous corneal dystrophy, which were treated with penetrating limbokeratoplasty-4 eyes of 3 patients had already undergone multiple conventional corneal transplantations. We evaluated the follow-up regarding recurrences of the disease, graft rejections, clear graft survival and incidence of secondary glaucoma with the Kaplan-Meier method.
Median age at surgery was 35 years. Postoperative treatment included topical steroids and systemic mycophenolate mofetil in all patients. Median graft survival was 6 years. Median time to a recurrence was 3 years. Median time to the first endothelial graft rejection was 2.5 years.
Penetrating limbokeratoplasty offers a possibility to restore visual acuity over a long period of time. However, gelatinous corneal dystrophy remains a therapeutic challenge. Even with simultaneous transplantation of cornea and limbal stem cells, recurrences of the disease cannot be prevented permanently. This is also connected with discontinuing a sufficient local and systemic immunosuppression.
凝胶状角膜营养不良在欧洲和北美是一种非常罕见的疾病。患者通常在20岁之前就会出现疼痛、畏光和视力丧失等症状。由于传统穿透性角膜移植术后复发率高,因此提出了角膜缘干细胞移植的方法。我们报告了穿透性角膜缘移植术(一种角膜和角膜缘干细胞联合移植术)治疗凝胶状角膜营养不良患者的结果。
我们报告了一系列连续7只患有凝胶状角膜营养不良的眼睛,这些眼睛接受了穿透性角膜缘移植术——3例患者的4只眼睛已经接受过多次传统角膜移植。我们采用Kaplan-Meier方法评估了疾病复发、移植物排斥、透明移植物存活情况以及继发性青光眼的发生率。
手术时的中位年龄为35岁。所有患者术后治疗均包括局部使用类固醇和全身使用霉酚酸酯。移植物中位存活时间为6年。复发的中位时间为3年。首次发生内皮移植物排斥的中位时间为2.5年。
穿透性角膜缘移植术提供了长期恢复视力的可能性。然而,凝胶状角膜营养不良仍然是一个治疗挑战。即使同时移植角膜和角膜缘干细胞,也无法永久预防疾病复发。这也与停止充分的局部和全身免疫抑制有关。